INTRODUCTION {#sec1-1}
============

Glucocorticoids (GCs) are a class of steroid hormones released from the adrenal cortex and their plasma concentration is controlled by the hypothalamic-pituitary-adrenal axis.\[[@ref1]\] GCs are mediators of stress response and the derived drugs (also named corticosteroids) are widely used as pharmacological agents for the treatment of inflammatory disease, asthma, and immune/rheumatologic diseases.\[[@ref2]\] However, approximately 20% of patients receiving high doses of corticosteroids develop psychiatric disorders including depression, mania, and psychosis\[[@ref3]\] requiring pharmacological treatment, while 75% report psychiatric symptoms reversible upon discontinuation of therapy.\[[@ref4]\]

Glucocorticoid activity: An overview {#sec2-1}
------------------------------------

Endogenous glucocorticoids affect biological processes including growth, metabolism, development, immune function, and stress response.\[[@ref5]\] The production of corticosteroid hormones is under the control of the hypothalamic-pituitary-adrenal axis, activated by mental and physical stimuli.\[[@ref6]\]

They are lipophilic hormones crossing the cytoplasmic membrane and binding to specific cytosolic receptors, mineralocorticoid receptors (MR), and glucocorticoid receptors (GR) that regulate gene expression. The drug-receptor complex can trigger the transcription of anti-inflammatory genes such as NF-kB, AP-1, STAT, NFTA, c-Jun, Fos, and inhibit the production of cytokines and pro-inflammatory proteins such as chemotactic proteins and adhesion molecules.\[[@ref7][@ref8][@ref9]\]

There are approximately 550 polymorphisms identified for the gene coding for the glucocorticoid receptors related to sensitivity to their effects.\[[@ref10]\]

Glucocorticoids possess several endocrinological properties being involved in several physiological and pathological processes; they have known effects on glucose metabolism, lipid metabolism, bone and cartilage, protein metabolism, muscular function, hydro-electrolytic balance, gastric secretion, cardiovascular system, hemolymphopoietic tissue, and reproductive physiology.\[[@ref11]\]

Endogenous glucocorticoids also control the feeling of hunger, sleep-wake cycle and affect the processes of learning and memory through interaction with specific receptors located in the prefrontal cortex, hippocampus, and basolateral amygdala.\[[@ref12]\]

Steroid receptors are expressed in different areas of the brain and their role is related to the regulation of various neurotransmission, including serotonin and dopamine.\[[@ref13]\] In particular, in the CNS, glucocorticoids exert their potential effects at hippocampal level, a structure intimately involved in the limbic system, which provides the processing of emotional information and memory.\[[@ref14]\] Various studies show a correlation between high levels of endogenous cortisol and hippocampal atrophy resulting in damage and cognitive dysfunction.\[[@ref15]\] Negative feedback ensures the activation of the hypothalamic-pituitary-adrenal axis by inducing the overproduction of cortisol and increasing the damage to brain structures.\[[@ref16]\]

CNS adverse events {#sec2-2}
------------------

Besides their very common therapeutic use, several well-known adverse effects including weight gain, osteoporosis, and hyperglycemia are often observed.\[[@ref17]\] Less-reported adverse events are that involving the central nervous system (CNS) such as psychiatric and cognitive disturbances \[[Table 1](#T1){ref-type="table"}\].
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Behavioral effects {#sec2-3}
------------------

Studies showed that following the chronic intake of cortisone, 70% of patients report increased appetite with resulting increase of body weight; a 4 to 8% increase is estimated after two years of therapy.\[[@ref18]\] Sleep disorders characterized by restlessness and insomnia were observed in 73% of cases.\[[@ref19]\] Swinburn *et al*. in 1988\[[@ref20]\] reported a study showing that patients with Chronic Obstructive Pulmonary Disease, treated with oral prednisolone, develop a sense of well-being called "steroid euphoria" characterized by a reduced sense of anxiety and depression when compared with patients receiving placebo and this occurred even in the absence of improvement in lung function. There are cases, in literature, that describe the appearance of altered behavior with states of agitation and insomnia as a result of intra-articular injection of methylprednisolone.\[[@ref21]\]

Recently, in a set of psychiatric symptoms attributed to prolonged treatment or high-dose corticosteroids, catatonia was assessed with muscle stiffness, insomnia, and abnormal behaviors such as silence and stillness.\[[@ref22]\]

Psychic effects {#sec2-4}
---------------

Literature reports several cases of depression related to the use of corticosteroid therapy with an incidence of 40.5%; mania, psychosis, and delirium are also very frequent with an incidence of 27.8%, 13.9%, and 10.1%, respectively.\[[@ref23]\] Emotional lability and irritability are common symptoms sometimes accompanied by auditory hallucinations and paranoia.\[[@ref22]\] Rarely, altered consciousness and disorientation may be observed.

The mechanism by which the corticosteroid induces symptoms such as mania, depression, and psychosis is not clear.\[[@ref22]\] The administration of prednisone is associated with decreased levels of corticotrophin, norepinephrine, and beta-endorphin in the cerebrospinal fluid. Furthermore, corticosteroids induce an increased release of glutamate that induces neuronal toxicity due to accumulation effect.\[[@ref23]\]

Cognitive effects {#sec2-5}
-----------------

In some cases, cognitive deficits, difficulty to maintain concentration, and poor memory, especially after prolonged treatment with high doses of corticosteroids, were observed.\[[@ref23]\] Neuroimaging studies in patients taking corticosteroids have related a decrease of hippocampal volume and brain atrophy due to a reduced blood flow in areas of the brain responsible for cognitive functions.\[[@ref24]\]

The cognitive effects of corticosteroids appear to be occasional and include disorders, which consist of dementia or delirium. The type of deficiency coincides with the dysfunction at hippocampal level, which is rich in glucocorticoid receptors.\[[@ref25]\]

Incidence {#sec2-6}
---------

A small percentage (2-4%) of patients develop depression, anxiety, or becomes apathetic.\[[@ref26]\] While another small percentage (3%) shows psychosis with hallucinations. These adverse events are dose and time dependent and remission results from the suspension of the treatment or decreasing the dose of cortisone.\[[@ref27]\] The incidence of neuropsychiatric effects due to assumption of corticosteroid ranges from 2 to 60%, reflecting the variability of dose, the duration of administration, and risk factors identified including genetic predisposition based on polymorphisms of the GR.\[[@ref28]\]

The incidence rate of psychiatric disorders is directly correlated to dose and time of glucocorticoids exposure. A study shows that the incidence rate was 22.2% person-years at risk for first courses, 14.0% person-years at risk for second glucocorticoid courses, and 11.7% person-years at risk for third and later courses.\[[@ref29]\]

Onset {#sec2-7}
-----

The beginning of the appearance of symptoms induced by corticosteroids is variable. They may arise in the first phases of treatment, during, or even at the end of therapy.\[[@ref30]\] In most cases (86%), they occur within the first 5 days of treatment. The analysis of several studies leads to an average of 11.5 days after the beginning of corticosteroid treatment to the onset of psychiatric symptoms.\[[@ref31]\] 89% of patients develop symptoms in the first six weeks, 62% within two weeks, and 39% in the first week. The duration of the neuropsychiatric effects is highly variable and depends on the severity, treatment discontinuation, and by other drug therapies.\[[@ref31]\]

Risk factors {#sec2-8}
------------

Side effects of psychiatric type have been reported following different routes of administration, e.g., intra-articular injection, epidural, topical, and systemic.

Psychiatric side effects due to corticosteroids appear to be dose dependent; they occur in 1.3% of the cases when the dose is less than 40 mg daily and reaches 18.4% for doses of 80 mg daily.\[[@ref32]\]

It is not entirely clear whether gender affects the ability to manifest psychiatric symptoms, but some studies suggest that women are more prone.\[[@ref33]\]

Other studies show that 73% of the pediatric population receiving steroid therapy develops hyperactivity, irritability, insomnia as well as showing deficits of attention and memory, especially those under 10 years of age and/or high doses of the drug.\[[@ref32]\]

Treatment {#sec2-9}
---------

Generally, symptoms related to administration of corticosteroids disappear after therapy discontinuation.\[[@ref34]\] However, some patients require therapeutic treatment. The management of psychiatric symptoms due to administration of corticosteroids includes the reduction of the dose or treatment discontinuation.\[[@ref35]\] The patient can be treated with medications normally used in patients with psychiatric or neurological disorders. Mood-stabilizing drugs, such as lithium and valproic acid, are able to control the symptoms caused by corticosteroids. Carbamazepine, inducing steroids metabolism, reduces their neurotoxic effects; atypical antipsychotics, such as olanzapine and fluoxetine (SSRI), are active on this symptoms.\[[@ref36]\] The effect of anti-depressive drugs are different, i.e., tricyclic antidepressants could lead to a significant worsening of symptoms,\[[@ref35]\] while a selective serotonin reuptake inhibitors, such as fluoxetine,\[[@ref37]\] may improve symptoms of depression during corticosteroid therapy as well as phenytoin, lamotrigine, risperidone, quetiapine, and gabapentin.\[[@ref37]\]

CASE REPORT {#sec1-2}
===========

In 2012, in our Pharmacovigilance\'s Center (Regione Calabria, University Hospital Mater Domini of Catanzaro) a suspected adverse reaction of paraphasia, a language disorder manifested by a difficulty to order words in periods, induced by intramuscular administration of betamethasone was reported.

Regarding this case, the correlation was very high since the patient was not taking other drugs in that period and the adverse reaction appeared 2 hours after the first injection.

Unfortunately, amnesic information is limited since it is an ambulatory patient. We know that it is a middle-aged man, without family history of mental illness and under therapy with angiotensin receptor blocker for hypertension since few years. Reporting low back pain for few months and suspecting a herniated disc, the physician prescribed computerized tomography, documenting bulging lumbar, and steroid therapy was prescribed. Since the beginning of betamethasone (Bentelan®) therapy, the patient was noted to have phenomena characterized by inversion of the letters while talking. Discontinuation of treatment was advised; after treatment interruption, the phenomena disappeared.

In literature, similar cases have not been previously reported; however, many studies show a correlation between psychiatric disorders and corticosteroids use.

Psychiatric disorders secondary to corticosteroids-use are classified as mood disorders substance-induced according to the Diagnostic and Statistical Manual of Disorders Fourth Edition (DSM-IV).\[[@ref38]\]

DISCUSSION AND CONCLUSIONS {#sec1-3}
==========================

Many scientific and literature evidences highlight how the administration of corticosteroids results in a high incidence of mood elevation, satisfaction, and optimism.\[[@ref39]\] Less frequently, euphoria, insomnia, and increase in motor activity may occur.\[[@ref40]\]

The use of corticosteroids is strongly associated to the development of psychiatric/neurological side effects. These effects are due to the wide expression of GR in the brain, and their long-term modulation can lead to functional and anatomical alterations, which might be responsible for the observed side-effects. The incidence and the onset of such symptoms are quite variable depending on several factors and the type of study; in any case, all healthcare professionals should be aware of such a possibility. Furthermore, such events should be early recognized and treated.

Despite of the known numerous side effects, the use of corticosteroid is widely spread considering the broad spectrum of clinical indications. Psychiatric adverse reactions are under-estimated and therefore it is not always possible to identify the effective dose and at the same time the most secure. It seems only right to recall how the spontaneous reporting of adverse reactions by health professionals and patients is the easiest way to integrate the missing information on the potential and dangers of drugs.
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